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RESEARCH ARTICLE
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Abstract Cancer-associated fibroblasts (CAFs) are a heterogeneous population of mesenchymal

*For correspondence:
faccior@wustl.edu
Competing interests: The
authors declare that no
competing interests exist.

cells supporting tumor progression, whose origin remains to be fully elucidated. Osterix (Osx) is a
marker of osteogenic differentiation, expressed in skeletal progenitor stem cells and bone-forming
osteoblasts. We report Osx expression in CAFs and by using Osx-cre;TdTomato reporter mice we
confirm the presence and pro-tumorigenic function of TdTOSX+ cells in extra-skeletal tumors.
Surprisingly, only a minority of TdTOSX+ cells expresses fibroblast and osteogenic markers. The
majority of TdTOSX+ cells express the hematopoietic marker CD45, have a genetic and phenotypic
profile resembling that of tumor infiltrating myeloid and lymphoid populations, but with higher
expression of lymphocytic immune suppressive genes. We find Osx transcript and Osx protein
expression early during hematopoiesis, in subsets of hematopoietic stem cells and multipotent
progenitor populations. Our results indicate that Osx marks distinct tumor promoting CD45- and
CD45+ populations and challenge the dogma that Osx is expressed exclusively in cells of
mesenchymal origin.
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In the past couple of decades the common beliefs of how an incipient tumor grows and progresses
to a metastatic stage have drastically changed due to the increasing findings of a tight crosstalk
between tumor cells and the surrounding stroma, known as the tumor microenvironment (TME)
(Hanahan and Weinberg, 2011). Tumor stroma comprises a variety of different cells from the mesenchymal and hematopoietic compartments, with pro- and anti-tumor functions. Cancer-associated
fibroblasts (CAFs) are cells of the mesenchymal lineage involved in supporting various stages of
tumorigenesis from growth to metastatic dissemination (Kalluri and Zeisberg, 2006; Chen and
Song, 2019). Their abundance and phenotypic markers differ among the various types of cancers.
CAFs support tumor growth by stimulating tumor cell proliferation, inhibiting apoptotic signals and
anti-tumor immune responses, altering the extra-cellular matrix (ECM) to favor invasiveness, and by
offering protection from chemotherapeutic approaches. Their heterogeneity probably accounts for
the different tumor promoting effects and reflects the fact that CAFs can originate from multiple cellular sources (Chen and Song, 2019). Several studies indicate that CAFs derive from bone marrow
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mesenchymal stem and progenitor cells recruited at the tumor site. Additional evidence indicates
that they can also derive from myofibroblasts, as well as from the trans-differentiation of local pericytes, endothelial and epithelial cells. In breast cancer, subsets of bone marrow-derived CAFs can
exhibit a unique inflammatory profile depending on the location to which they are recruited, thus
being functionally distinct from the resident CAFs and having better tumor-promoting functions
(Raz et al., 2018). Adding more complexity to the origin of CAFs, an additional population expressing several markers commonly found in fibroblasts and CAFs, is the fibrocyte (Abe et al., 2001;
McDonald and LaRue, 2012; van Deventer et al., 2013). Fibrocytes originate from the bone marrow, where they have been described to contribute to bone marrow fibrosis under pathological conditions (Ohishi et al., 2012). These cells have also been implicated in supporting tumor progression,
but they differ from the bone marrow-derived CAF populations in that they also express the hematopoietic marker CD45, along with markers associated with the monocyte/macrophage lineage populations (Abe et al., 2001). Fibrocytes support tumor growth by making collagen, albeit at lower
levels than the CAFs, releasing growth factors, commonly produced by immune suppressive myeloid
cells, and by modulating resistance to anti-angiogenic therapy (Goto and Nishioka, 2017). Recent
single-cell RNA sequencing (scRNAseq) studies further confirmed the complexity of the CAF populations, suggesting tumor specificity as well as functional differences among the various subsets
(Bartoschek et al., 2018; Costa et al., 2018; Elyada et al., 2019). However, these studies did not
directly address the origin of the various subsets, which could account for their specific cellular
phenotype.
Because of their ability to produce collagen and other extracellular matrix proteins, we sought to
determine whether a subset of bone marrow-derived CAFs could share markers of committed osteolineage cells. Osteolineage cells derive from bone marrow mesenchymal stem cells (MSCs) and their
differentiation program is driven by sequential activation of two specific transcription factors, Runx2
and Sp7(Osx gene), and subsequent acquisition of a phenotype characterized by the ability to produce bone matrix, primarily type I collagen, and to mineralize (Nakashima et al., 2002). Although
Osx is largely thought as a marker of differentiated osteoblasts, emerging data demonstrate that in
the embryonic and perinatal bone marrow Sp7 is expressed in definitive MSCs that give rise to the
marrow stroma, including osteoblasts and adipocytes (Liu et al., 2013; Mizoguchi et al., 2014). Furthermore, during embryogenesis, Osx is present in extra-skeletal tissues, including the olfactory
bulb, the intestine and the kidney (Chen et al., 2014; Jia et al., 2015).
Based on the above observations, we hypothesized that a subset of CAFs, derived from Osx+
cells in the bone marrow, contributes to ECM (i.e. collagen) production at the tumor site, thereby
creating a tumor supporting stroma. Using a cell tracking system, we found the presence of cells targeted by the Osx promoter within the TME; these TdTOSX+ cells favor tumor growth when coinjected with tumor cells in mice. Surprisingly, only a minority of tumor-resident cells derived from
Osx+ cells expresses fibroblast markers, extracellular matrix and matrix remodeling genes. The
majority of these newly identified TdTOSX+ tumor infiltrating cells are also positive for CD45, a
marker of hematopoietic lineage, and share markers expressed by tumor-infiltrating immune cells.
Importantly, we confirmed Sp7 transcripts and Osx protein in a subset of hematopoietic stem cells
(HSC), giving rise to TdTOSX+;CD45+ tumor infiltrating immune populations. This study further identifies new populations of TME cells targeted by Osx and challenges the use of Osx-cre driven lineage
tracing mouse models to exclusively study mesenchymal lineage cell fate.

Results
Embryonic and adult-derived osteolineage Osx+ cells are present in
extra-skeletal tumors
To determine whether osteolineage cells may be present in the TME, we crossed the established tetracycline-dependent Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J (Osx-cre) to the B6.Cg-Gt(ROSA)26Sortm9
(CAG-tdTomato)Hze/J (TdT) to generate the Osx-cre;TdT reporter mouse model (Rodda and
McMahon, 2006). When constitutively activated, TdT marks the entire osteolineage, including bone
surface osteoblasts, osteocytes and bone marrow cells with mesenchymal stem and osteoprogenitor
cell features; while delaying Osx-cre expression until postnatally restricts TdT targeting to committed
osteoblasts and osteocytes (Mizoguchi et al., 2014; Fontana et al., 2017). Therefore, Osx-cre;TdT

Ricci et al. eLife 2020;9:e54659. DOI: https://doi.org/10.7554/eLife.54659

2 of 29

Research article

Cancer Biology Immunology and Inflammation

mice and control animals carrying only the TdT transgene (WT;TdT) were kept on standard chow to
allow constitutive embryonic transgene activation, or fed a doxycycline (doxy)-containing diet until
weaning to suppress transgene activation until one month of age (Figure 1A). We previously
reported that doxy-fed mice display less than 1% of spontaneous recombination in the bone residing
osteoblasts at weaning, but full transgene activation 1 month thereafter (Fontana et al., 2017).

Figure 1. Embryonic and adult-derived Osx+ cells are present in primary tumors at extra-skeletal sites. (A)
Doxycycline (doxy)-repressible Sp7-cre/loxP mouse model used to activate Ai9/TdTomato expression for lineage
tracing experiments. In no doxy-fed mice, TdT is expressed in embryonic-derived osteolineage cells (left), while in
mice fed a doxy diet until weaning, TdT is expressed in adult-derived osteolineage cells. (B–I) Flow cytometry
analysis and fluorescence images of primary tumors showing presence of TdTOSX+ cells in no-doxy fed Osx-cre;
TdT mice or WT;TdT controls inoculated with B16-F10 melanoma subcutaneously (B–C), or with PyMT breast
cancer cells in the mammary fat pad (MFP) (D–E), and in doxy-fed mice injected with B16-F10 subcutaneously (F–
G), or with PyMT in the MFP (H–I). Slides for fluorescence images were counterstained with DAPI (blue),
magnification 200X. Inserts are further magnified 4.5 folds. Data representative of a single experiment,
experiments were repeated between 2 and 5 times. p values represent Student t-test statistical analysis.
The online version of this article includes the following source data and figure supplement(s) for figure 1:
Source data 1. Relates to FACS analysis in panels B, D, F, H.
Figure supplement 1. No difference in tumor growth and body weight between sex and age matched cre
positive (Osx-cre;TdT) and negative (WT;TdT) mice.
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Osx-cre;TdT reporter mice and WT;TdT fed a normal diet (no doxy) were inoculated with either
105 B16-F10 melanoma cells subcutaneously or 105 PyMT breast cancer cells in the mammary fat
pad (MFP). To account for the possible growth delay sometimes observed in no-doxy fed Osx-cre
mice (Davey et al., 2012), tumor cells were injected at 12 weeks of age, when the growth delay is
fully recovered. Importantly, no differences in tumor growth were observed in age and sex matched
Osx-cre;TdT and WT;TdT mice, excluding any potential confounding effect of the Osx-cre (Figure 1—figure supplement 1). To assess the presence of osteolineage Osx+ derived cells within the
tumor stroma of no doxy-fed mice, we performed flow cytometry analysis on B16-F10 and PyMT
tumors isolated 2 weeks post-inoculation, and found that about 10–18% of the total cells were
TdTOSX+ (Figure 1B and D). Histological analysis of frozen sections from the same tumors confirmed
the presence of TdTOSX+ cells. These cells had either round or elongated shape, indicating morphologic heterogeneity within the TdTOSX+ population (Figure 1C and E). These TdTOSX+ cells within
the tumor stroma of no-doxy mice may derive from resident Osx-expressing embryonic progenitors
or from mobilization of bone marrow Osx+ cells.
Remarkably, TdTOSX+ cells were also present in the B16-F10 and PyMT TME of doxy-fed animals
4 weeks post weaning, although their numbers were lower than in tumors isolated from no doxytreated mice (Figure 1F and H). Fluorescence micrographs also confirmed the presence of TdTOSX+
cells in the stroma in both tumor models (Figure 1G and I), with the same pleiotropic morphology
as seen in no doxy-treated mice. Thus, embryonic and adult-derived osteolineage Osx+ cells are
present in the stroma of extra-skeletal tumors. Based on these findings, the doxy-fed Osx-cre;TdT
mice were used for all the subsequent studies.

TdTOSX+ cells from primary tumors express mesenchymal markers
To determine the phenotype of TdTOSX+ cells more in depth, we isolated TdTOSX+ cells by FACS
sorting 14 days after inoculation of B16-F10 tumor cells into doxy-fed Osx-cre;TdT reporter mice
(Figure 2A). Due to the limited number of TdTOSX+, tumors from 2 to 4 mice were pooled for FACS
sorting and reported as one experimental replicate (single data point). Messenger RNA from an
immortalized murine CAF cell line (i-CAFs) and cortical long bone devoid of bone marrow cells were
used as controls. Real-Time PCR confirmed Sp7 expression in TdTOSX+ cells but not in the TdTOSX–
fraction, which includes the remaining stroma and the tumor cells (Figure 2B). Interestingly, Sp7
expression was also detected in i-CAFs (Figure 2B), and as expected in bone extracts in higher
abundance. Expression of osteoblast-specific markers such as Runx2, Bglap (Ocn) (Osteocalcin), Ibsp
(Bsp, bone sialoprotein) and Alpl (Tnap, tissue non-specific alkaline phosphatase) were negligible in
TdTOSX+ cells and undetectable or barely detectable in the i-CAFs (Figure 2C–F). However, S100a4
(Fsp1) (Fibroblast-specific protein 1) and Acta2 (a-SMA) (a-smooth muscle actin), two CAFs specific
markers, were detected in TdTOSX+ cells (Figure 2G and H). TdTOSX+ also expressed Col1a1 (Collagen Type Ia1) and Col1a2 (Collagen Type Ia2) similar to i-CAFs and bone extracts (Figure 2I and J).
Expression of matrix metalloproteinases, Mmp2 and Mmp9, involved in matrix remodeling and
highly expressed in CAFs and osteoblasts respectively, was also detected in the TdTOSX+ cells
(Figure 2K and L).
To validate expression of Sp7 in CAFs from primary tumors, we orthotopically injected B16-F10
or PyMT cells in 8 week old WT mice and the CAFs were isolated as the adherent fraction of a single
cell suspension of the tumor mass. We detected Sp7 expression only in CAFs but not in the tumor
cell lines nor in the non-adherent fraction of the single cell suspension from the tumor mass
(Figure 2M and N). Importantly, corroborating our findings in mice, using Oncomine (Rhodes et al.,
2004) we found that microarray analysis of human breast stromal cells collected from patients with
invasive breast carcinoma from the Finak gene set (Finak et al., 2008) showed significantly higher
Sp7 expression in the tumor associated stroma compared to the adjacent normal breast tissue
(Figure 2O). Thus, a subset of cells in the TME of mice and humans express Sp7, an osteolineage
cell marker, but also markers associated with the CAFs. TdTOSX+ cells may represent a subpopulation of CAFs with specific features.
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Figure 2. TdTOSX+ cells from primary tumors express mesenchymal markers. (A) Experimental design for isolating
TdTOSX+ cells from primary tumors isolated from doxy-fed Osx-cre;TdT mice inoculated with B16-F10. TdTOSXcells comprise all TdT negative cells including the tumor cells. Immortalized CAFs (iCAFs) and crushed long bones
were used as reference controls. (B–L) Quantitative Real-Time PCR for (B) Sp7(Osterix), (C) Runx2, (D) Bglap
(Osteocalcin), (E) Ibsp (Bone sialoprotein), (F) Alpl (Tnap, Tissue non-specific alkaline phosphatase), (G) S100a4
(Fsp1), (H) Acta2 (a-SMA) (I) Collagen1a1 (J) Collagen1a2, (K) Mmp2 (Metalloproteinase2) and (L) Mmp9
(Metalloproteinase9) genes in TdTOSX+, TdTOSX- cells, iCAFs and bone. Each data point includes cells isolated
from 3 to 4 mice and from two independent experiments. (M–N) Real-Time PCR of Sp7(Osterix) in B16-F10 or
PyMT cell lines, CAFs isolated from primary B16-F10 or PyMT tumors or from the remaining cells comprising the
tumor minus the CAFs (susp) (n = 3–4 mice). (O) Sp7(Osx) expression based on the Finak Breast Cancer Stroma
gene set in the Oncomine cancer microarray database. Significance was determined by one-way ANOVA with
Tukey post-hoc test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
The online version of this article includes the following source data for figure 2:
Source data 1. Relates to Real-Time PCR data.
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Tumor resident but not bone marrow resident TdTOSX+ cells increase
tumor growth
To determine whether tumor resident TdTOSX+ cells can affect tumor growth as do CAFs, TdTOSX+
cells were sorted from primary B16-F10 tumors inoculated in 8 week old doxy-fed Osx-cre;TdT mice
and re-injected along with B16-F10 tumor cells at 5:1 ratio into age-matched WT recipient animals
(Figure 3A). Remarkably, co-injecting TdTOSX+ with tumor cells resulted in larger tumors (Figure 3B)
compared to injection of B16-F10 cells alone.
Because TdTOSX+ cells normally reside in the bone microenvironment (Fontana et al., 2017;
Strecker et al., 2013), we next examined bone sections from 8 week old doxy-fed Osx-cre;TdT
reporter mice, naı̈ve or bearing soft tissue B16-F10 or PyMT tumors. We confirmed presence of
TdTOSX+ cells on the surface of cortical and trabecular bone, TdTOSX+ osteocytes, and also abundant staining in the bone marrow. TdT was not detected WT;TdT mice (Figure 3C and Figure 3—
figure supplement 1A). We further analyzed the percentage of TdTOSX+ cells in the bone marrow
by FACS and found that TdTOSX+ cells accounted for about 10% of total marrow cells in naı̈ve mice
and their number increased in mice injected with B16-F10 or PyMT tumor cells (Figure 3D and Figure 3—figure supplement 2B). Similar findings were observed in the Tamoxifen (TAM) inducible
Sp7-creERT2; Rosa26<fs-TdTomato> (Osx-creERT2;TdT) mouse model. TAM was administered to 7 week
old mice via IP injections starting 3 days prior to B16-F10 tumor inoculation, and 1, 6, and 9 days
post tumor cell injection (Figure 4—figure supplement 1A). No tumor bearing mice were used as
control. Similar to the Tet-OFF Osx-cre model, we found that bone marrow TdTOSX+ cells significantly increased in presence of a tumor (Figure 3E).
To test their capacity to promote tumor growth, bone marrow-derived TdTOSX+ cells were isolated from tumor bearing mice and re-injected with B16-F10 tumor cells into WT mice (5:1 ratio). In
contrast to what observed with tumor-derived TdTOSX+ cells, bone marrow-derived TdTOSX+ cells
did not enhance tumor growth compared to mice injected with tumor cells alone; if anything, there
was a trend towards a smaller tumor size (Figure 3F). This result further prompted us to isolate
bone marrow-derived TdTOSX+ cells and analyze the expression levels of the same mesenchymal
genes analyzed in the tumor-derived TdTOSX+ cells (Figure 2). Interestingly, TdTOSX+ cells from the
TME expressed higher levels of Sp7, CAF markers S100a4 and Acta2, and matrix proteins Col1a1
and Ibsp compared to TdTOSX+ from the bone marrow (Figure 3—figure supplement 2). Bone marrow TdTOSX+ cells instead expressed significantly higher levels of the early osteoblast transcription
factor Runx2 and of the protease Mmp9, while no differences in other osteoblast markers such as
Bglap and Alpl were detected between the tumor and bone marrow sorted TdTOSX+ cells (Figure 3—figure supplement 2).
These results suggest that Osx+ cells infiltrating a tumor are functionally and phenotypically distinct from bone marrow resident Osx+ cells.

The majority of TdTOSX+ cells express CD45
To gain insights on the possible origin of tumor-derived TdTOSX+ cells, we performed FACS analysis
of circulating cells in naı̈ve mice and two weeks post B16-F10 or PyMT tumor inoculation. Interestingly, we found 5–8% of TdTOSX+ cells in the blood of tumor-free doxy-fed Osx-cre;TdT mice, and
this percentage was 3- to 4-fold higher in tumor-bearing animals (Figure 4A and B). The unexpected
high number of circulating TdTOSX+ cells prompted us to determine whether they may express the
immune marker CD45, which is also present in fibrocytes. Surprisingly, 95% of TdTOSX+ cells in circulation of tumor bearing mice were also positive for CD45, and they represented about 13–18% of
total blood cells (Figure 4C and D). Similarly, about 92–95% of total TdTOSX+ cells in the bone marrow were CD45+ (Figure 4E and F), representing 12–20% of total marrow cells. Such finding
explained the low expression levels of mesenchymal markers in the bone marrow-derived TdTOSX+
cells (Figure 3—figure supplement 2). Intriguingly, also the majority of TdTOSX+ cells in the TME
expressed CD45 (Figure 4G and H), data further confirmed by RT-PCR in TdTOSX+ fraction sorted
from B16-F10 tumors (not shown).
To exclude a possible off-target effect of the doxy-dependent Tet-OFF system, we turned to the
TAM inducible Osx-creERT2;TdT model. FACS analysis confirmed presence of both CD45- and
CD45+ TdTOSX+ populations in the bone marrow of B16-F10 bearing Osx-creERT2;TdT mice, but not
in the cre negative mice (Figure 4—figure supplement 1B).
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Figure 3. Tumor resident but not bone marrow resident TdTOSX+ cells increase tumor growth. (A) Model showing isolation of TdTOSX+ cells from B16F10 primary tumors injected into doxy-fed Osx-cre;TdT mice and re-inoculation of TdTOSX+ cells together with B16-F10 tumor cells into WT recipient
mice at the ratio 5:1. Mice injected with B16-F10 alone were used as controls. (B) Tumor growth of experimental model described in (A) determined by
caliper measurement. n = 3/group, experiment repeated twice. Significance was determined by one-way ANOVA with Tukey post-hoc test. (C)
Fluorescence images of bone sections showing presence of TdTOSX+ within the bone and bone marrow of naı̈ve Osx-cre;TdT, Osx-cre;TdT mice
inoculated subcutaneously with B16-F10 tumors or WT;TdT mice used as negative control. Sections were counterstained with DAPI (blue), magnification
200X. (D–E) Quantification of TdTOSX+ cells in the bone marrow of tumor-free and B16-F10 tumor bearing (D) Osx-cre;TdT mice (doxy-fed) and (E) OsxcreERT2;TdT (TAM-treated) determined by FACS. Experiment repeated twice. Significance was determined by student t-test statistical analysis. (F)
Tumor growth of WT mice inoculated with bone marrow-derived TdTOSX+ cells from B16-F10 bearing doxy-fed Osx-cre;TdT mice together with B16F10 tumor cells (ratio 5:1). Mice injected with B16-F10 alone were used as controls. n = 3/group. Significance was determined by two-way ANOVA
followed by Tukey post-hoc test. ***p<0.001, ****p<0.0001.
The online version of this article includes the following source data and figure supplement(s) for figure 3:
Figure supplement 1. TdTOSX+ cells increase in the bone marrow of PyMT tumor bearing mice.
Figure supplement 1—source data 1. Relates to FACS analysis.
Figure supplement 2. Differential expression of mesenchymal markers in TdTOSX+ cells isolated from tumor site or bone marrow.
Figure supplement 2—source data 1. Relates to Real-Time PCR.
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Figure 4. TdTOSX+ cells express the immune surface marker CD45. (A–B) Representative FACS dot plots and quantification of TdTOSX+ cells in the
peripheral blood of tumor-free and B16-F10 or PyMT tumor bearing mice. Significance was determined by student t-test statistical analysis for each
tumor model relative to no tumor controls. (C–D) Representative FACS dot plots and quantification of TdTOSX+;CD45+ and TdTOSX+;CD45populations in the blood of doxy-fed Osx-cre;TdT mice injected with B16-F10 or PyMT cells. (E–H) Representative FACS dot plots and quantification of
Figure 4 continued on next page
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Figure 4 continued
TdTOSX+;CD45+ and TdTOSX+;CD45- populations in the bone marrow (E–F) or tumor site (G–H) of doxy-fed Osx-cre;TdT mice injected with B16-F10 or
PyMT cells, respectively. Experiments were repeated at least twice. (I) Immunohistochemistry staining of paraffin-embedded B16-F10 tumors inoculated
into Osx-cre;TdT reporter mice, pseudo colored with red representing TdTOSX+ cells (RFP stained), green representing CD45+ cells (DAB stained) and
blue representing nuclei (hematoxylin), magnification 200X.
The online version of this article includes the following source data and figure supplement(s) for figure 4:
Source data 1. Relates to FACS analysis in panels B, C, D, E, F, G, H.
Figure supplement 1. Presence of TdTOSX+ cells in bone marrow (BM) of TAM-pulsed Osx-creERT2;TdT reporter mice.
Figure supplement 1—source data 1. Relates to FACS analysis.
Figure supplement 2. Co-expression of Osx-driven TdTomato and the immune marker CD45.

Next, to confirm that expression of CD45 in the TdTOSX+ cells was not due a tight interaction
between a CD45+ immune cell and TdTOSX+ mesenchymal cell, we performed CD45 immunostaining on paraffin-embedded B16-F10 tumor sections and on bone marrow single cell suspension from
Osx-cre;TdT reporter mice. We found co-localization of Osx-driven TdTomato and CD45 in the same
cell, confirming that CD45 is indeed expressed in subsets of TdTOSX+ cells (Figure 4I and Figure 4—
figure supplement 2). Thus, Osx not only marks mesenchymal cells, but also cells expressing the
hematopoietic marker CD45, suggesting that they could represent bone marrow fibrocytes or an
immune cell subset.

Presence of functionally distinct populations of TdTOSX+ cells in the
tumor microenvironment
To further characterize the phenotype of the CD45- and CD45+ TdTOSX+ populations, we next performed RNAseq analysis. We subcutaneously injected the GFP-labeled PyMT-BO1-tumor line in Osxcre;TdT reporter mice. Two weeks post tumor inoculation, the stromal cells were separated from the
GFP+ tumor cells and sorted based on the expression, or lack of thereof, of TdT and CD45 markers.
We sorted 4 groups of cells: double negative (TdTOSX-;CD45-), representing the non-immune tumor
stroma, CD45 single positive (TdTOSX-;CD45+), representing the tumor infiltrating immune populations, TdTOSX single positive (TdTOSX+;CD45-), and double positive (TdTOSX+;CD45+).
Principal components analysis of RNA-seq expression patterns across all four groups revealed
clustering that was uniquely dependent on CD45 expression and suggested that there were only
two very distinct cell populations regardless of TdTOSX (Figure 5A). Inspection of each cell population in a one versus all other approach for only statistically significant up-regulated genes
(FDR >= 0.05, log2 fold-change >= 2) to identify robustly expressed biomarkers, showed that all
four groups shared many genes in common based on CD45 expression alone. The CD45 negative
populations shared 1248 genes in common with 536 in the TdTOSX single positive and 477 in the
double negative cells uniquely up-regulated (Figure 5B). Likewise, the CD45 single and double positive cells shared 495 significantly up-regulated genes with an additional 77 and 316 uniquely
expressed, respectively.
Subsequent Gene Ontology (GO) analysis of the log2 fold-changes for each cell population
revealed that the CD45 negative subsets showed upregulation of GO pathways related to cellular
responses to growth factors, extracellular structure and matrix organization and skeletal system
development, confirming their mesenchymal nature (Figure 5C). Among the top upregulated genes
in the TdTOSX single positive cells versus the double negative (Table 1) we found several markers
expressed by osteolinage cells, such as fibromodulin (Fmod), a binding protein regulating bone mineralization (Gori et al., 2001) and also involved in TGFb signaling during cancer pathogenesis
(Pourhanifeh et al., 2019), Collagen 24a1 (Col24a1), known to modulate collagen chain trimerization (Koch et al., 2003; Matsuo et al., 2006), Frem1, a protein involved in the formation and organization of basement membranes (Vissers et al., 2011), and Msx1, a transcription factor important in
craniofacial bone development (Orestes-Cardoso et al., 2002). TdTOSX single positive cells also
expressed high levels of fibulin 7 (Fbln7), a cell adhesion molecule overexpressed in glioblastoma by
pericytes and involved in neovascularization (de Vega et al., 2019; Ikeuchi et al., 2018). Such result
confirmed the osteolineage nature of the TdTOSX+ cells and indicated their tumor supporting role.

Ricci et al. eLife 2020;9:e54659. DOI: https://doi.org/10.7554/eLife.54659

9 of 29

Research article

Cancer Biology Immunology and Inflammation

Figure 5. TdTOSX+;CD45- and TdTOSX+;CD45+ are two functionally distinct populations in the tumor
microenvironment. (A) Multidimensional Principal Component Analysis of RNAseq data obtained from four tumor
stroma subsets sorted according to TdTOSX and CD45 expression. (B) Venn diagram depicting uniquely and
commonly expressed genes among the four groups. (C–D) First ten GO pathways obtained from the GO analysis
of the log two fold-changes for (C) CD45 negative subsets and (D) CD45 positive subsets.
The online version of this article includes the following source data and figure supplement(s) for figure 5:
Figure supplement 1. Validation of RNAseq data.
Figure supplement 1—source data 1. Relates to Real-Time PCR data.

Conversely, both CD45+ subsets were significantly up-regulated for GO pathways related to regulation of lymphocyte activation and proliferation, and innate immune cell responses (Figure 5D).
Interestingly, among the top genes upregulated in the TdTOSX+ CD45+ subsets versus the CD45 single positive populations (Table 2), we found many genes expressed by tumor promoting immune
cells, such as regulatory T cells (i.e. Foxp3) and gamma-delta T cells (i.e. Tcrg-C1). The most upregulated gene in the TdTOSX+;CD45+ subset (>80 fold versus CD45 single positive) was Cd163l1, a
marker of gamma-delta IL-17 producing cells (Tan et al., 2019) and M2 macrophages (GonzálezDomı́nguez et al., 2015), two tumor-promoting immune populations. We confirmed Cd163l1 higher
expression by RT-PCR together with other two genes, Wdr78 and Spock2, also upregulated in the
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Table 1. Top 50 uniquely up-regulated genes in tumor-derived TdTOSX+;CD45- cells.
List of the 50 most highly expressed genes in the TdTOSX+;CD45- cells compared to the TdTOSX-;CD45- cells isolated from the TME.

external_gene_name

description

TdTOSX
+CD45logFC

TdTOSX
+CD45linearFC

Reg1

regenerating islet-derived 1

7.675801

204.477899

Fbln7

fibulin 7

7.184048

145.416614

Adcyap1r1

adenylate cyclase activating polypeptide 1 receptor 1

6.864422

116.51905

Col24a1

collagen, type XXIV, alpha 1

6.788179

110.521192

Moxd1

monooxygenase, DBH-like 1

6.74623

107.35382

Fmod

fibromodulin

6.739645

106.864989

4930562D21Rik

RIKEN cDNA 4930562D21 gene

6.149924

71.008705

Angpt4

angiopoietin 4

6.131627

70.113799

Tmem132c

transmembrane protein 132C

5.933002

61.095844

Frem1

Fras1 related extracellular matrix protein 1

5.906166

59.969876

Cxcl5

chemokine (C-X-C motif) ligand 5

5.88881

59.252728

Ccl19

chemokine (C-C motif) ligand 19

5.748355

53.756054

Rab15

RAB15, member RAS oncogene family

5.696057

51.842269

Prlr

prolactin receptor

5.673651

51.04334

Msx1

msh homeobox 1

5.657661

50.480738

Pabpc4l

poly(A) binding protein, cytoplasmic 4-like

5.657301

50.46814

Reg3g

regenerating islet-derived 3 gamma

5.651841

50.2775

Rflna

refilin A

5.651765

50.274843

Adamts3

a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 3

Lrp3

low density lipoprotein receptor-related protein 3

Clstn2
Adam5
H2-M11

5.52646

46.092506

5.465865

44.196651

calsyntenin 2

5.41628

42.703438

a disintegrin and metallopeptidase domain 5

5.36495

41.210775

histocompatibility 2, M region locus 11

5.335531

40.378937

Ptx3

pentraxin related gene

5.320565

39.962237

Rtl3

retrotransposon Gag like 3

5.252916

38.131634

Gm26682

predicted gene, 26682

5.252803

38.128648

Morc1

microrchidia 1

5.251594

38.096689

Hoxc6

homeobox C6

5.176329

36.160165

Mcpt8

mast cell protease 8

5.146576

35.422062

Gabrb3

gamma-aminobutyric acid (GABA) A receptor, subunit beta 3

5.110873

34.556218

Sbspon

somatomedin B and thrombospondin, type 1 domain containing

5.085426

33.952042

Akap6

A kinase (PRKA) anchor protein 6

5.073102

33.663235

Hmcn1

hemicentin 1

5.060346

33.366905

Aqp2

aquaporin 2

5.031264

32.701036

Gria3

glutamate receptor, ionotropic, AMPA3 (alpha 3)

5.011924

32.265589

AI464131

expressed sequence AI464131

5.001414

32.03138

Muc13

mucin 13, epithelial transmembrane

4.997132

31.936452

Syt4

synaptotagmin IV

4.994666

31.881898

Spon1

spondin 1, (f-spondin) extracellular matrix protein

4.916033

30.190712

Caln1

calneuron 1

4.85996

29.039801

Hoxc4

homeobox C4

4.844155

28.723415

Tbx2

T-box 2

4.842042

28.681376

Table 1 continued on next page
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Table 1 continued

external_gene_name

description

TdTOSX
+CD45linearFC

TdTOSX
+CD45logFC

Jph2

junctophilin 2

4.816833

28.18456

Frzb

frizzled-related protein

4.79214

27.706253

Galnt5

polypeptide N-acetylgalactosaminyltransferase 5

4.77782

27.432606

Gm29100

predicted gene 29100

4.77255

27.332593

Tspyl5

testis-specific protein, Y-encoded-like 5

4.771509

27.312867

Spag17

sperm associated antigen 17

4.770653

27.296671

Ldoc1

regulator of NFKB signaling

4833422C13Rik

RIKEN cDNA 4833422C13 gene

4.7479

26.86954

4.730678

26.550693

double positive cells (Figure 5—figure supplement 1). The second most expressed gene was Lymphotoxin beta (Ltb), a cytokine produced by lymphocytes and NK cells and associated with carcinogenesis (Wolf et al., 2010). The third one, Klrg1, negatively regulates cytotoxic lymphocytes and is
associated with lymphocyte senescence and dysfunction (Henson and Akbar, 2009). Thus, these
analyses revealed that two main transcriptional programs predominate based on CD45 expression,
and suggest that TdTOSX+;CD45- comprise a subset of CAFs with some characteristics of skeletal
cells, while TdTOSX+;CD45+ cells represent a heterogeneous subset of tumor-promoting immune
cells.

Double positive TdTOSX+;CD45+ cells are a heterogeneous immune
population enriched in lymphoid cells
Next we performed flow cytometry analysis to better characterize the TdTOSX+;CD45+ population
and validate some of the RNAseq findings using the B16-F10 melanoma model. We confirmed that
the double positive TdTOSX+;CD45+ represented about 20% of the total CD45+ cells in both the primary tumor and the bone marrow of doxy-fed Osx-cre;TdT mice (Figure 6A and B). Next, we analyzed the percentage of TdTOSX+ expressing the common myeloid and lymphoid markers (gate
strategy in Figure 6—figure supplement 1), such as CD11b (monocytes), F4/80 (macrophages), Gr1
(granulocytes/neutrophils), CD3 (T cells, further divided into CD4+ and CD8+), and NK1.1 (Natural
Killer cells). To standardize the comparison between the TdTOSX+;CD45+ and TdTOSX-;CD45+ (single positive) populations within each sample, data were represented as percentage of either total
TdTOSX+;CD45+ or total CD45 single positive cells (Figure 6C and D). TdTOSX+;CD45+ subset
expressed both myeloid and lymphoid markers, with a similar pattern as the CD45 single positive
cells. In both subsets, the majority of the tumor immune infiltrate included myeloid populations,
which represented about 60% of the TdTOSX+;CD45+ and over 70% of the total CD45 single positive
cells. Lymphoid cells appeared to be more abundant among the TdTOSX+;CD45+ (32.3 ± 6.5%),
compared to the TdTOSX-;CD45+ cells (23.3 ± 4.3%). Based on this observation, we calculated the
ratio of lymphoid over myeloid populations and observed that the tumor-infiltrating TdTOSX+;CD45
+ double positive population was enriched in lymphoid cells (Figure 6E). Flow cytometric analysis of
the bone marrow from tumor bearing Osx-cre;TdT mice revealed similar pattern of distribution
between the TdTOSX+;CD45+ and the CD45 single positive immune populations (Figure 6F and G),
although the frequencies of each immune subset in the bone marrow differed compared to the cells
at tumor site. These data suggest that Osx marks multiple immune cell types but that TdTOSX+derived immune cells infiltrating a tumor are skewed towards lymphoid populations.
Since adoptive transfer of tumor-derived TdTOSX+ cells increases tumor growth (Figure 3B), we
asked whether TdTOSX+;CD45+ immune populations contribute to tumor progression. We isolated
by FACS sorting TdTOSX+;CD45+ and the TdTOSX-;CD45+ from B16-F10 subcutaneous tumors from
doxy-fed Osx-Cre;TdT mice. Sorted cells were then re-injected along with B16-F10 tumor cells (ratio
5:1) into new WT recipient mice. The co-injection of CD45 single positive cells decreased tumor
growth relative to B16-F10 injected alone at day 15, while TdTOSX+;CD45+ did not show anti-tumor
effects (Figure 6H).
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Table 2. Top 50 uniquely up-regulated genes in tumor-derived TdTOSX+;CD45+ cells.
List of the 50 most highly expressed genes in the TdTOSX+;CD45+ cells compared to the TdTOSX-;CD45+ cells isolated from the TME.
external_gene_
name

description

TdTOSX+CD45+
logFC

TdTOSX+CD45+
linearFC

Cd163l1

CD163 molecule-like 1

6.482112

89.394369

Ltb

lymphotoxin B

6.217037

74.389998

Klrg1

killer cell lectin-like receptor subfamily G, member 1

5.915697

60.367363

Foxp3

forkhead box P3

5.882423

58.991007

Trbv19

T cell receptor beta, variable 19

5.83901

57.242322

Cd5

CD5 antigen

5.822965

56.609196

Gm4759

predicted gene 4759

5.712238

52.426999

Tcrg-C1

T cell receptor gamma, constant 1

5.709921

52.342868

Icos

inducible T cell co-stimulator

5.588856

48.129715

Gm19585

predicted gene, 19585

5.577582

47.755056

Fasl

Fas ligand (TNF superfamily, member 6)

5.571314

47.548033

Rln3

relaxin 3

5.518062

45.824955

Ubash3a

ubiquitin associated and SH3 domain containing, A

5.432308

43.180511

Pcsk1

proprotein convertase subtilisin/kexin type 1

5.376329

41.537117

Ccr8

chemokine (C-C motif) receptor 8

5.32423

40.06386

Gimap3

GTPase, IMAP family member 3

5.257508

38.253185

Slamf1

signaling lymphocytic activation molecule family member 1

5.220641

37.288037

Klrb1f

killer cell lectin-like receptor subfamily B member 1F

5.204067

36.86212

Ikzf3

IKAROS family zinc finger 3

5.185332

36.386518

Trdv4

T cell receptor delta variable

5.179288

36.234394

Trat1

T cell receptor associated transmembrane adaptor 1

5.144648

35.374755

Pdcd1

programmed cell death 1

5.092017

34.107504

Izumo1r

IZUMO1 receptor, JUNO

5.053635

33.212045

Cd3e

CD3 antigen, epsilon polypeptide

5.042174

32.949246

Itk

IL2 inducible T cell kinase

5.027182

32.608632

Ctla4

cytotoxic T-lymphocyte-associated protein 4

4.978043

31.516668

Actn2

actinin alpha 2

4.919967

30.27316

Trbv1

T cell receptor beta, variable 1

4.891164

29.674756

Dkkl1

dickkopf-like 1

4.820628

28.258804

Cd300e

CD300E molecule

4.801355

27.883791

Pglyrp2

peptidoglycan recognition protein 2

4.80032

27.863797

Cd226

CD226 antigen

4.766441

27.21709

Themis

thymocyte selection associated

4.760082

27.097397

Dpep3

dipeptidase 3

4.694473

25.892693

Cd209a

CD209a antigen

4.650261

25.111233

Cd27

CD27 antigen

4.648725

25.084512

Gpr55

G protein-coupled receptor 55

4.621113

24.608975

Ccr6

chemokine (C-C motif) receptor 6

4.596004

24.18439

Gpr174

G protein-coupled receptor 174

4.594683

24.16225

A630023P12Rik

RIKEN cDNA A630023P12 gene

4.586499

24.025577

Cd28

CD28 antigen

4.564255

23.657981

Cd3g

CD3 antigen, gamma polypeptide

4.547609

23.386577

Lta

lymphotoxin A

4.534293

23.171712

Table 2 continued on next page
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Table 2 continued
external_gene_
name

description

TdTOSX+CD45+
logFC

TdTOSX+CD45+
linearFC

Ccr3

chemokine (C-C motif) receptor 3

4.526527

23.047318

Gzmb

granzyme B

4.518658

22.921957

Lrrc66

leucine rich repeat containing 66

4.47147

22.184347

Xirp2

xin actin-binding repeat containing 2

4.462937

22.053513

St8sia1

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1

4.460924

22.022769

Sit1

suppression inducing transmembrane adaptor 1

4.417363

21.367754

Tnfrsf4

tumor necrosis factor receptor superfamily, member 4

4.381868

20.84844

Figure 6. Subsets of myeloid and lymphoid cells in the tumor microenvironment and the bone marrow are derived
from TdTOSX+ cells. (A–B) Quantification of FACS analysis showing the percentage of TdTOSX+;CD45+ and
TdTOSX-;CD45+ populations in the tumor and bone marrow of Osx-cre;TdT mice injected subcutaneously with
B16-F10 tumor cells. Data showed as % of total CD45+ cells. (C–D) Quantification of FACS analysis showing the
percentage of tumor infiltrating myeloid and lymphoid populations within the TdTOSX+;CD45+ or TdTOSX-;CD45+
subsets, each considered as 100%. (E) Lymphoid over myeloid ratio within the tumor infiltrating TdTOSX+;CD45+
or the TdTOSX-;CD45+ subsets. Statistical analysis was performed by student t-test. (F–G) Quantification of FACS
analysis showing the percentage of the bone marrow resident myeloid and lymphoid populations within the
TdTOSX+;CD45+ or TdTOSX-;CD45+ subsets, each considered as 100%. n = 3/group. (H) Tumor growth in mice
injected with B16-F10 tumor cells alone or together with tumor-derived TdTOSX+;CD45+ or TdTOSX-;CD45+ cells
at the ratio 1:5. n = 3–6/group.
The online version of this article includes the following source data and figure supplement(s) for figure 6:
Source data 1. Relates to FACS analysis.
Figure supplement 1. Gate strategy for immune staining of tumor and bone marrow.
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Collectively, these data indicate that Sp7 marks cells of both mesenchymal and hematopoietic origin to support the development of tumor promoting populations.

Double positive TdTOSX+;CD45+ cells derive from TdTOSX+ HSCs
To determine whether Sp7 may be activated at early stages of hematopoiesis as a potential explanation for the heterogeneity of TdTOSX+;CD45+ cells, we performed flow cytometric analysis for
hematopoietic stem cell (HSC) markers in the bone marrow of doxy-fed Osx-cre;TdT and TAMinduced Osx-creERT2;TdT mice bearing B16-F10 tumors subcutaneously. We analyzed the lineage
negative (Lin-) LSK and LK populations (Figure 7A) gated based on the expression of Sca1 and c-kit
and found 10.9–11.45% TdTOSX+ LSK and 7.08–8.94% TdTOSX+ LK in Osx-cre;TdT and Osx-creERT2;
TdT mice, respectively (Figure 7B and D). The LSK population was further divided into HSC and multipotent progenitor MPP(1-4) subsets (Figure 7A and gate strategy in Figure 7—figure supplement
1). Interestingly, TdTOSX+ cells represented about 30% of MPP1, and between 7–11% of the MPP2MPP3 and MPP4 subsets in Osx-cre;TdT mice (Figure 7C). Similar results were also obtained in OsxcreERT2;TdT mice (Figure 7E). The slight difference in frequency between the two mouse models
could depend on the different timing of Cre activation, but both models succeeded to find TdTOSX+
cells in HSCs.
Importantly, RT-PCR of isolated HSCs from the bone marrow of 7–8 week old wild-type naı̈ve
mice showed Sp7 expression compared to the TdTOSX- fraction isolated from the tumor mass, used
as negative control (Figure 8A). Similarly, Sp7 transcripts were found in the MPP1-4 subsets, and in
the common lymphoid progenitors CLP, but not in the common myeloid progenitors CMP

Figure 7. TdTOSX+;CD45+ cells derive from TdTOSX+ HSCs. (A) Schematic of hematopoietic differentiation. (B–E)
Flow cytometry quantification of TdTOSX+ cells in the bone marrow of (B–C) doxy-fed Osx-cre;TdT mice and (D–E)
TAM-treated Osx-creERT2;TdT mice injected subcutaneously at 7 weeks of age with B16-F10 tumors. In (B and D)
LSK and LK subsets are shown, while in (C and E) the LSK population is further divided into HSCs and MPP1-4
subsets. Red numbers represent the average of TdTOSX+ cells in each specific subset. n = 2–6/group.
The online version of this article includes the following source data and figure supplement(s) for figure 7:
Source data 1. Relates to FACS analysis.
Figure supplement 1. Gate strategy for HSC immunostaining of bone marrow.
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Figure 8. Sp7 transcripts and Osx protein are expressed in a subset of HSCs isolated from bone marrow of naı̈ve mice. (A) Real Time PCR analysis
comparing sorted hematopoietic stem cells (HSC), multipotent progenitors (MPP), common myeloid progenitors (CMP), common lymphoid progenitors
(CLP) and whole bone marrow (WBM) from 7 to 9 week old mice. FACS sorted TdTOSX- cells from the tumor of Osx-cre;TdT mice were used as negative
control (n = 3–8/group). Statistical analysis was determined by two-way ANOVA followed by Tukey post-hoc test. *p<0.05, **p<0.01, ***p<0.001,
Figure 8 continued on next page
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Figure 8 continued
****p<0.0001. (B) Real Time PCR analysis of isolated mature CD3+ T cells, conventional dendritic cells (cDC) and bone marrow-derived
macrophages (mj) from WT naı̈ve mice. (C–E) Immunofluorescence for Osx in (C) primary osteoblasts differentiated from BMSC cultured for 4 days in
osteogenic media, (D) TdTOSX+ HSCs sorted from Osx-cre;TdT reporter mice and (E) whole bone marrow cells from WT mice. DAPI is used for nuclear
staining. Magnification 200X.
The online version of this article includes the following source data for figure 8:
Source data 1. Relates to Real-Time PCR in panels A, B.

(Figure 8A). In contrast, RT-PCR analysis of mature immune populations from naı̈ve mice (macrophages, dendritic cells and T cells) failed to detect Sp7 expression (Figure 8B). Finally, we performed immunostaining for Osx to confirm protein expression on a single cell level. To enrich for
Osx+ cells, we FACS sorted TdTOSX+ HSCs from the bone marrow of Osx-cre;TdT reporter mice
after enrichment for c-kit+ cells. Sorted cells were plated on serum-coated coverslips for two days
before immunostaining for Osx and with DAPI for nuclear localization. We confirmed Osx localization
in the nuclei of the majority of TdTOSX+ HSCs (Figure 8D). As positive control for Osx staining, we
used bone marrow stromal cells isolated from WT mice cultured for 4 days in osteogenic medium
(Figure 8C). Whole bone marrow was used as additional control confirming that only a small number
of cells expressed Osx while the majority was negative (Figure 8E). Thus, for the first time we show
that subsets of HSCs express the transcription factor Sp7, giving rise to tumor infiltrating immune
populations.

Discussion
Numerous studies have established the importance of the TME for primary tumor growth and metastatic dissemination (Goubran et al., 2014). In skeletal metastases, crosstalk between bone residing
cells, osteoblasts and osteoclasts, and tumor cells drives tumor growth (Weilbaecher et al., 2011).
Recent studies also suggest that osteoblasts and their secretory products stimulate the expansion of
bone marrow-derived myeloid populations, which in turn escape the bone marrow and reach distant
sites to support tumor growth by inhibiting anti-tumor immune responses (D’Amico et al., 2016;
Engblom et al., 2017). Our study demonstrates that a transcription factor required for osteoblast
differentiation, Osterix, marks pro-tumorigenic stromal cells infiltrating extra-skeletal tumors. A possible role of Osx in tumorigenesis is emerging from human studies as well showing that presence of
Sp7 in the tumor is associated with poor patient survival (Yao et al., 2019). Our own analysis of published gene microarray data of breast cancer stroma (Finak et al., 2008), reveals higher Sp7 expression in tumor stroma relative to healthy tissue from the same subject, corroborating the notion that
Osx+ stromal cells regulate tumor growth. Therefore, Osx function may well extend beyond its
known role in bone development and homeostasis.
Osterix has been primarily studied in the context of osteoblast differentiation and regulation of
bone mass. Sp7 deficient mice die within 1 hr of birth with a complete absence of intramembranous
and endochondral bone formation (Nakashima et al., 2002; Baek et al., 2009). During embryogenesis and perinatally, Sp7 is expressed in MSCs in the bone marrow, and it is necessary for the full
osteogenic program. In adult mice, Sp7 is mainly confined to committed osteoblasts and osteocytes.
There is increasing evidence of Sp7 expression in cells residing outside the skeleton, including synovial fibroblasts (Miura et al., 2019), dental pulp (Monterubbianesi et al., 2019), olfactory glomerular cells, gastric and intestinal epithelium (Chen et al., 2014), and kidney (Strecker et al., 2013).
Here we demonstrate that Sp7 is also present in a CAF subset, and in hematopoietic precursors,
thus challenging the dogma that Sp7 is exclusively expressed by mesenchymal cells. Our cell tracking studies using the repressible Tet-OFF Osx-cre;TdT reporter and the tamoxifen-inducible OsxcreERT2;TdT model demonstrate the presence of TdTOSX+;CD45+ cells in the bone marrow of adult
mice. At least two other independent studies have also shown abundant and persistent Osx+ cells in
the bone marrow when the reporter gene is activated either embryonically or neonatally (Liu et al.,
2013; Mizoguchi et al., 2014), and at 3 weeks of age (Strecker et al., 2013), but no signal in the
bone marrow when the Osx-cre is activated after 8 weeks of age (Mizoguchi et al., 2014). Notably,
most of the studies with Osx-cre reporter mice have excluded the hematopoietic marker CD45 in
the analysis of the Osx+ populations, and no report to date has shown Sp7 expression in the
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hematopoietic compartment. Importantly, we also report that bone marrow residing TdTOSX+ populations expand during tumor progression. Such result is highly unlikely linked to systemic factors
released from extra-skeletal tumors enhancing the Tet-transactivator in the Tet-OFF;Osx-cre;TdT
mice. In fact, we observed increased TdTOSX+ cells (CD45- and CD45+ subsets) also in the bone
marrow of tumor bearing Osx-creERT2;TdT animals. Our findings are instead consistent with previous
observations reporting increased numbers of bone marrow residing MSCs and osteoblast precursors
in mice and patients with lung adenocarcinomas (Engblom et al., 2017), and with the reprogramming of hematopoiesis towards increased myelopoiesis during tumor progression (Capietto et al.,
2013; Meyer et al., 2018).
Here, we report for the first time that a subset of hematopoietic lineage cells in the bone marrow
and at tumor site derives from an Osx+ progenitor, which is present embryonically and persists until
7–8 weeks of age. Importantly, we detected Sp7 transcripts and Osx nuclear localization in a subset
of HSCs. These results support the observation that TdTOSX+;CD45+ cells are very heterogeneous
and express monocyte, macrophage, granulocyte, T cell and NK cell markers. The heterogeneity of
the TdTOSX+;CD45+ populations is most likely derived from expression of Sp7 in HSC and MPP subsets. These precursors can give rise to the lineage committed common lymphoid (CLP) and myeloid
(CMP) progenitors that differentiate into all the mature immune cells (Pietras et al., 2015). Sp7 transcripts are also detected in CLP but not in CMP or mature immune populations, indicating that Osx
is activated early during hematopoiesis, with higher expression in cells committed to the lymphoid
lineage. Despite expressing both myeloid and lymphoid markers, we noted increased in lymphoid
over myeloid ratio in the TdTOSX+;CD45+ tumor infiltrating cells relative to the TdTOSX-;CD45+ cells.
TdTOSX+;CD45+ subset is also enriched in genes expressed by immunosuppressive or exhausted
lymphocytes. Such result is consistent with the functional tumor co-injection studies showing that
TdTOSX-;CD45+ cells reduce tumor growth while the TdTOSX+;CD45+ subset does not.
Co-injection of tumor cells with cells sorted from the primary tumor has been used to validate the
pro-tumorigenic roles of CAFs and certain immune suppressive CD45+ populations. Here, we show
that tumor-derived TdTOSX+ cells, comprising both CD45 positive and negative subsets, increase
tumor growth compared to tumor cells injected alone. By contrast, co-injection of bone marrowderived TdTOSX+ cells with the tumor cells does not exert any pro-tumor effect suggesting that
bone marrow-derived TdTOSX+ cells are functionally distinct from tumor-derived TdTOSX+ cells.
Hence, if tumor-derived TdTOSX+ cells originate from the bone marrow in response to an incipient
tumor, as it would be anticipated by their increase in the circulation of tumor-bearing mice, they
must undergo a conditioning process within the TME to acquire a pro-tumorigenic function. Because
Osx regulates expression of proteins required for the generation of the bone tissue, it is likely that a
main role of Osx+ mesenchymal cells (TdTOSX+;CD45-) in the TME is to produce and remodel extracellular matrix. Fibroblasts with an osteoblast signature involved in matrix production have been
recently identified by single cell RNA sequencing in rheumatoid arthritis (Croft et al., 2019). ECM
accumulation is quite frequent within the TME, causing in more severe cases an intense fibrotic
response, or desmoplasia, and tumor stiffening (Gkretsi and Stylianopoulos, 2018). Stiffening is not
only required for a primary tumor to displace the host tissue and grow in size, but also contributes
to cell–ECM interactions and can promote cancer cell invasion to surrounding tissues (Gkretsi and
Stylianopoulos, 2018). As noted earlier, upregulation of Sp7 in breast cancer cells is associated with
increased invasion and bone metastasis, and this may occur by upregulation of ECM modifying metalloproteinases, MMP9 and MMP13, and other factors that increase vascularization, and affect bone
cell function (Yao et al., 2019).
Since Sp7 is not expressed in mature immune populations, it is difficult to envision a role for Osx
in modulating anti-tumor immune responses. Co-injection experiments indicate that TdTOSX+;CD45
+ cells have better pro-tumorigenic function than TdTOSX–;CD45+ cells. However, only the co-injection of the bulk TdTOSX+ cells increases tumor growth over the B16-F10 tumor cells alone, suggesting that the Osx+ mesenchymal population (TdTOSX+;CD45-) is responsible for enhancing tumor
growth. This finding is intriguing since the TdTOSX+;CD45- mesenchymal cells represent only 5% of
the total tumor infiltrating TdTOSX+ populations. One could speculate that TdTOSX+;CD45- cells represent a subset of highly pro-tumorigenic CAFs, which can support tumor progression even when
present in very limited numbers. Another possibility is that the TdTOSX+;CD45- mesenchymal cells
might be required to create and maintain an immune suppressive environment where the CD45+
populations fail to exert anti-tumor effects.
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In conclusion, we demonstrate that Sp7 is expressed in a subset of tumor infiltrating mesenchymal
cells with CAF and osteogenic cell features. Surprisingly, Sp7 expression is also found in hematopoietic precursors, and marks tumor infiltrating immune populations enriched in immune suppressive
markers. Considering the emerging data that Sp7 expression in the tumor cells is linked to tumor
progression, our results emphasize the importance of Osx in the TME and the need to evaluate the
prognostic value of stromal Sp7 expression in the patients.

Materials and methods
Key resources table
Reagent type
(species) or resource Designation

Source or reference Identifiers

Additional
information

Gene
(Mus musculus)

Sp7(Osx)

NCBI Gene

RRID:MGI:2153568

NCBI ID:170574

Genetic
reagent
(Mus musculus)

Tg(Sp7-tTA,tetO-EGFP
/cre)1Amc/J
(Osx-cre)

The Jackson
Laboratories

Cat#006361
RRID:MGI:3689350

C57Bl/6

Genetic
reagent
(Mus musculus)

B6.Cg-Gt(ROSA)26Sortm9
(CAG-tdTomato)Hze/J
(TdT)

The Jackson
Laboratories

RRID:MGI3813511

C57Bl/6

Genetic
reagent
(Mus musculus)

Sp7-creERT2/Ai9tdTomato
(Osx-creERT2;TdT)

PMID:31768488

Cat#007909
RRID:MGI:4829803

Prof. Silva MJ
(Washington University
in St Louis)
C57Bl/6

Cell line
(Mus musculus,
C57Bl/6)

B16-F10 melanoma cell line

ATCC

RRID:CRL-6475-LUC2 C57Bl/6

Cell line
(Mus musculus)

PyMT breast
cancer cell line

PMID:27216180

Prof. Weilbaecher KN
(Washington
University in St Louis)
C57Bl/6

Cell line
(Mus musculus)

Immortalized Cancer
Associated
Fibroblast cell line

PMID:27264173

Prof Longmore GD
(Washington
University in St Louis)

Antibody

Rat anti-mouse
CD45-APCeFluor780
(clone 30-F11)

eBioscience

Cat #47-0451-82
RRID:AB_1548781

FACS (1:400)

Antibody

Rat anti-mouse CD45-PE
Cy7 (clone 30-F11)

eBioscience

Cat #25-0451-82
RRID:AB_2734986

FACS (1:400)

Antibody

Rat anti-mouse CD11bAlexaFluor700 (clone M1/70)

eBioscience

Cat#56-0112-82
RRID:AB_657585

FACS (1:400)

Antibody

Rat anti-mouse Gr1(Ly6G)
-FITC (clone RB6-8C5)

Miltenyi Biotec

Cat#130-102-837
RRID:AB_2659858

FACS (1:100)

Antibody

Rat anti-mouse F4/80
PerCP Cy5.5 (clone BM8)

Biolegend

Cat#123126
RRID:AB_10802654

FACS (1:400)

Antibody

Hamster anti-mouse
CD3e-PE (clone 145–2 C11)

eBioscience

Cat#A14714
RRID:AB_2534230

FACS (1:200)

Antibody

Rat anti-mouse CD4-APC
(clone RM4-5)

BD Biosciences

Cat#553051
RRID:AB_398528

FACS (1:200)

Antibody

Rat anti-mouse CD8a-FITC
(clone 53–6.7)

BD Biosciences

Cat#561966
RRID:AB_10896291

FACS (1:200)

Antibody

Mouse anti-mouse NK1.1
(clone PK136)

Biolegend

Cat#108722
RRID:AB_2132712

FACS (1:200)

Antibody

Rat anti-mouse CD45R
(B220)-Biotin (clone RA3-6B2)

eBioscience

Cat#13-0452-82
RRID:AB_466449

FACS (0.4 ul/sample)

Antibody

Hamster anti-mouse
eBioscience
CD3e-Biotin (clone 145–2 C11)

Cat#13-0031-82
RRID:AB_466319

FACS (0.4 ul/sample)

Continued on next page
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Continued
Reagent type
(species) or resource Designation

Source or reference Identifiers

Additional
information

Antibody

Rat anti-mouse Ter119
(clone TER119)

eBioscience

Cat# 13-5921-82
RRID:AB_466797

FACS (0.4 ul/sample)

Antibody

Rat anti-mouse Ly-6G/Ly-6C
Biotin (clone RB6-8C5),

eBioscience

Cat#13-5931-82
RRID:AB_466800

FACS (0.2 ul/sample)

Antibody

Rat anti-mouse CD41Biotin
(clone MWReg30)

eBioscience

Cat#13-0411-82
RRID:AB_763484

FACS (1 ul/sample)

Antibody

Streptavidin-BV510

BD Biosciences

Cat#563261

FACS (0.5 ul/sample)

Antibody

Rat anti-mouse Sca-1 BV711
(clone D7)

BD Biosciences

Cat#563992
RRID:AB_2738529

FACS (0.25 ul/sample)

Antibody

Rat anti-mouse
c-kit(CD117)-APCeFluor780
(clone ACK2)

eBioscience

Cat#47-1172-82
RRID:AB_1582226

FACS (1 ul/sample)

Antibody

Rat anti-mouse CD16/32BUV395 (clone 2.4G2)

BD Biosciences

Cat#740217
RRID:AB_2739965

FACS (0.5 ul/sample)

Antibody

Rat anti-mouse CD34-FITC
(clone RAM34)

eBioscience

Cat#11-0341-82
RRID:AB_465021

FACS (4 ul/sample)

Antibody

Rat anti-mouse CD150
(SLAM)-BV421 (clone
TC15-12F12.2)

Biolegend

Cat#115943
RRID:AB_2650881

FACS (1 ul/sample)

Antibody

Hamster anti-mouse
CD48-PE Cy7
(clone HM48-1)

eBioscience

Cat#25-0481-80
RRID:AB_1724087

FACS (0.15 ul/sample)

Antibody

Rat anti-mouse
CD135(Flt3)-APC
(clone A2F10)

eBioscience

Cat#17-1351-82
RRID:AB_10717261

FACS (2 ul/sample)

Antibody

Rat anti-mouse
CD45 (clone 30-F11)

Invitrogen

Cat#14-0451-82
RRID:AB_467251

IF, IHC (1:200)

Antibody

Rabbit antimouse RFP/TdT

Rockland

Cat#600-401-379
RRID:AB_2209751

IF,IHC (1:500)

Antibody

Goat-anti-Rat IgG-Biotin

Thermo Fisher

Cat#31830
RRID:AB_228355

IF, IHC (1:500)

Antibody

Streptavidin-HRP

Bio-Rad

Cat#STAR5B

IF, IHC (1:500)

Antibody

Goat-anti-rabbit
Alexa-fluor647

Thermo Fisher

Cat#A21244
RRID:AB_2535812

IF (4 ug/ml)

Antibody

Rabbit antimouse Sp7/Osx

Abcam

Cat#ab227820

IF (1:500)

Antibody

Goat anti-rabbit
AlexaFluor488

Abcam

Cat#ab150077
RRID:AB_2630356

IF (1:1000)

Sequencebased reagent

Cyclophilin

This paper

PCR primers

5’-AGC ATA CAG GTC CTG GCA TC-3’
and
5’-TTC ACC TTC CCA AAG ACC AC-3’

Sequencebased reagent

Sp7(Osx)

This paper

PCR primers

5’-AAG GGT GGG TAG TCA TTT GCA-3’
and
5’-CCC TTC TCA AGC ACC AAT GG-3’

Sequencebased reagent

S100A4(Fsp-1)

This paper

PCR primers

5’-TGA GCA ACT TGG ACA GCA ACA-3’
and
5’-TTC CGG GGT TCC TTA TCT GGG-3’

Sequencebased reagent

Acta2(a-SMA)

This paper

PCR primers

5’-GTC CCA GAC ATC AGG GAG TAA-3’
and
5’-TCG GAT ACT TCA GCG TCA GGA-3’

Sequencebased reagent

Col1a1

This paper

PCR primers

5’-GGC CTT GGA GGA AAC TTT GC-3’
and
5’-GGG ACC CAT TGG ACC TGA AC-3’

Continued on next page
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Continued
Reagent type
(species) or resource Designation

Source or reference Identifiers

Additional
information

Sequencebased reagent

Bglap(Ocn)

This paper

PCR primers

5’-GGA CTG AGG CTC TGT GAG GT-3’
and
5’-CAG ACA CCA TGA GGA CCA TC-3’

Sequencebased reagent

Runx2

This paper

PCR primers

5’-GTT ATG AAA AAC CAA GTA GCC AGG-3’
and
5’-GTA ATC TGA CTC TGT CCT TGT GGA-3’

Sequencebased reagent

BSP

This paper

PCR primers

5’-AGG ACT AGG GGT CAA ACA C-3’
and
5’-AGT AGC GTG GCC GGT ACT TA-3’

Sequencebased reagent

TNAP

This paper

PCR primers

5’-GGG GAC ATG CAG TAT GAG TT-3’
and
5’-GGC CTG GTA GTT GTT GTG AG-3’

Commercial
assay or kit

TSA FITC System

Perkin Elmer

Cat#NEL701A001KT

Commercial
assay or kit

BOND Intense
R detection kit

Leica Biosystem

Cat#DS9263

Commercial
assay or kit

BOND Polymer Refine
Red detection kit

Leica Biosystem

Cat#DS9390

Commercial
assay or kit

Avidin/Biotin
Blocking kit

Vector Labs

Cat#SP2001
RRID:AB_2336231

Software,
algorithm

STAR

STAR

RRID:SCR_015899

Version 2.0.4b

Software,
algorithm

Subread

Subread

RRID:SCR_009803

Version 1.4.5

Software,
algorithm

R

R

RRID:SCR_001905

Version 3.4.1

Software,
algorithm

EdgeR

EdgeR

RRID:SCR_012802

Version 3.20.2

Software,
algorithm

LIMMA

LIMMA

RRID:SCR_010943

Version 3.34.4

Software,
algorithm

GAGE

GAGE

RRID:SCR_017067

Version 2.28.0

Other

VECTASHIELD Mounting
Medium with DAPI

Vector Labs

Cat#H1200
RRID:AB_2336790

one drop

Other

ProLong Gold with DAPI

Invitrogen

Cat#P10144

one drop

Tumor cell lines, CAF isolation and generation of primary cell cultures
B16-F10 (C57BL/6 mouse melanoma cell line, ATCC # CRL-6475-LUC2), PyMT and PyMT-BO1-GFP
(Su et al., 2016) (C57BL/6 mouse breast cancer cell lines), kindly provided by Prof. Katherine N Weilbaecher (Washington University in St. Louis), were cultured at 37˚C in complete media (DMEM supplemented with 2 mM l-glutamine, 100 mg/ml streptomycin, 100 IU/ml penicillin, and 1 mM sodium
pyruvate) containing 10% FBS. Immortalized CAF cell line was kindly provided by Prof. Gregory D
Longmore (Washington University in St. Louis). All the cell lines used have been tested for mycoplasma and were mycoplasma free. CAFs were isolated from primary tumors as described in
Corsa et al., 2016. Tumors were minced, digested and plated as single cell suspension on a tissue
plastic dish for 30 min to separate the adherent fraction, composed of CAFs, from the cells in suspension, comprising of tumor cells, tumor infiltrating immune populations and endothelial cells,
among few others. CAFs were then left 24 hr in culture and RNA was extracted afterwards.
Bone marrow stromal cells (BMSCs) were cultured in complete alpha-MEM (without ascorbic acid)
containing 10% FBS and differentiated for 4 days in osteogenic medium (complete alpha-MEM supplemented with 50 mg/ml ascorbic acid and 10 mM beta-glycerophosphate) to obtain preosteoblasts.
Sorted hematopoietic stem cells (HSCs) were plated overnight on a glass coverslip coated with
serum in the presence of StemPRO (Gibco) media and then fixed and used for immunostaining.
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Mouse strains and tumor models
Animals were housed in a pathogen-free animal facility at Washington University (St. Louis, MO,
USA). Age and sex-matched animals were used in all experiments according to IACUC guidelines.
B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J (catalog #006361; The Jackson laboratory, ME USA)
mice, which carry a tetracycline-responsive Osx promoter driving Cre (Osx-cre) were mated with
reporter mice B6.Cg-Gt(ROSA)26SorTm9(CAG-tdTomato)Hze/J (TdT) (catalog #007909; The Jackson Laboratory), to generate Osx-cre;TdT mice. To suppress Cre expression, 200ppm doxycyline (doxy) was
added to the chow (Test Diet #1816332–203, Purina, MO USA) and fed to some groups of mice until
weaning (P28); pups were switched to standard rodent chow at weaning. Sp7-creERT2/Rosa26<fsTdTomato>
mice were kindly provided by Prof. Matthew D Silva (Washington University in St. Louis).
Tamoxifen (#T5648, Millipore Sigma, MO USA) was dissolved in corn oil and injected at 100 mg/kg
intra-peritoneally. Wild-Type (WT) C57BL/6 mice were purchased from The Jackson Laboratory.
Subcutaneous (sq) injections were performed using 105 B16-F10 tumor cells suspended in 100 ml
of sterile PBS and Matrigel Matrix (Corning #354234), while 105 PyMT were suspended in 50 ml of
sterile PBS and Matrigel Matrix and injected into the MFP. Adoptive transfer and co-injection with
tumor cells were performed using a 5:1 ratio of TdTOSX+:B16-F10 tumor cells. The number of cells
injected in each experiment varied depending upon the number of cells obtained from sorting in
each experiment (hence, the differences in tumor size among the different experiments), but within
(2.5105:5104) and (5105:1105) cells. B16-F10 cells only were injected as control using the same
number of tumor cells co-injected with TdTOSX+ cells. Tumors were monitored by caliper measurements and mice were sacrificed between day 14 and 16 post tumor inoculation. Tumor volume was
calculated according to the formula: 0.5236*length*(width [Kalluri and Zeisberg, 2006]).

Flow cytometry and sorting
Single cell suspensions were prepared from fresh bone marrow and tumors upon sacrifice. Bone
marrow cells were obtained from femurs and tibias by centrifugation, while tumors were minced and
digested with 3.0 mg/ml collagenase A (Roche, Basel Switzerland) and 50 U/ml DNase I (Millipore
Sigma) in serum-free media for 45 min at 37˚C. Cells were filtered through 70 mm strainers, red
blood cells (RBC) were then removed with RBC lysis buffer (Millipore Sigma), washed twice in PBS
and stained in FACS buffer (0.5% BSA, 2 mM EDTA, 0.01%NaN3) with the following antibodies:
CD45 (clone 30-F11, eBioscience), CD11b (clone M1/70, eBioscience), Ly6G (Gr-1) (clone RB6-8C5,
eBioscience), F4/80 (BM8, Biolegend), CD3 (145–2 C11, eBioscience), CD4 (RM4-5, BD Biosciences),
CD8 (clone 53–6.7, BD Biosciences), NK1.1 (clone PK136, Biolegend). Once stained, cells were
sorted for the adoptive transfer, RT-PCR and RNAseq studies or were fixed for flow cytometry (gate
strategy in Figure 7—figure supplement 1) in BD Cytofix fixation buffer (BD Biosciences, 554655).
Samples were acquired using the BD LSR-Fortessa cytometer and analyzed with FlowJo version
9.3.2.
Hematopoietic stem cell subsets were analyzed from fresh bone marrow isolated from femurs,
tibias and hip bones crushed with mortar and pestle in 3 ml of PBS, filtered in a 70mm-nylon strainer
to remove bone fragments and lysed of red blood cells (RBC). 10 million cells were stained for each
sample using the following antibodies: CD3, Gr1, B220 (clone RA3-6B2, eBioscience), Ter119 (clone
TER119, e Bioscience), CD41 (clone eBioMWReg30, eBioscience) for lineage negative gating, Sca-1
(clone D7, BD Biosciences), CD117/c-kit (clone ACK2, eBioscience), CD16/32 (clone 2.4G2, BD Biosciences), CD34 (clone RAM34, eBioscience), CD150/SLAM (clone TC15-12F12.2, Biolegend), CD48
(clone HM48-1, eBioscience), CD135/Flt3 (clone A2F10, eBioscience), gate strategy in Figure 7—figure supplement 1. Once stained, cells were fixed in BD Cytofix fixation buffer, acquired using the
Bio-Rad ZE5 (YETI) cytometer and analyzed with FlowJo version 10.4.1.
Isolation of hematopoietic progenitor subsets for Real Time analysis was obtained by FACS sorting using the following markers: HSCs (Lineage- c-Kit+Sca-1+CD48-CD150+), MPPs (Lineage- c-Kit
+Sca-1+CD48-CD150-), CLPs (Lineage- c-Kit+Sca-1+IL7ra+Flt3+Ly6D-) and CMPs (Lineage- c-Kit
+Sca-1-CD34+CD16/32). For IF, TdTomato was also used to sort Osx+ HSCs.
Isolation of hematopoietic stem cells for Osx immunostaining was performed as following: whole
bone marrow was isolated from femurs, tibias and iliac crests and incubated with mouse CD117-conjugated microbeads (Miltenyi Biotec #130-091-224). CD117-enrichment was then carried out using
the AutoMACS Pro Seperator (Miltenyi Biotec). Post CD117 enrichment, the positive cell fraction
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was stained to sort phenotypically defined TdTomato+ HSCs (Lineage- c-Kit+Sca-1+CD48-CD150+)
by FACS.

Histology
Tumors and bones (femur and tibia) were fixed in 4% PFA over-night (ON) at 4˚C. The fixed bones
were partially decalcified in 14% EDTA for 3 days, washed in a sucrose gradient (1 hr in 10% sucrose,
1 hr in 20% sucrose, ON in 30% sucrose) before snap-freezing them in OCT embedding medium.
Tumors were directly put in sucrose gradient and then embedded in OCT. Frozen sections were cut
at 5 mm thickness and kept at 20˚C until analysis.
Thawed sections were washed in PBS and mounted with VECTASHIELD Mounting Medium containing DAPI (Vector Laboratories, CA USA).
Images were taken using the Leica DMi8 Confocal Microscopy at the Musculoskeletal Research
Center (Washington University in St Louis), magnification 200X.

Immunohistochemical staining
Tissues were fixed in 10% neutral-buffered formalin for 18 hr, embedded in paraffin after gradedethanol dehydration, and sectioned into 6 mm sections using a microtome. Automated staining was
carried out on the BondRxm (Leica Biosystems). Following dewaxing and citrate-buffered antigen
retrieval, sections were stained with the primary antibody for 1 hr at RT. Sequential chromogenic
detection was performed with the Bond IntenseR (Rat primary) and Bond Polymer Refine Red (Rabbit primary) detection kits (Leica Biosystems). The primary antibodies used were rat anti-CD45 (Invitrogen clone 30-F11, #14-0451-82) followed by rabbit anti-RFP/TdT (Rockland, # 600-401-379).
Stained sections were dehydrated in graduated ethanol and xylene washes then mounted with
xylene-based Cytoseal (Thermo Fisher).
Stained slides were imaged at 20X magnification with the Zeiss Axioscan slide scanner. For image
analysis, Halo v3 (Indica Labs) was used to deconvolve dual stained images into single channels and
pseudo colored with blue representing nuclei (hematoxylin), green representing CD45+ cells (DAB
stained), and red representing Osx+ cells (RFP stained).

Immunohistochemestry and immunofluorescence staining
For colocalization of TdT+ cells and CD45 in B16-F10 soft tissue tumors, subcutaneous tumors were
dissected and fixed in 10% neutral-buffered formalin for 18 hr, embedded in paraffin after gradedethanol dehydration, and sectioned into 6 mm sections using a microtome. Sections were dewaxed
in xylene and then hydrated through graded ethanol washes. Endogenous peroxidases were
quenched by incubating in hydrogen peroxide (1% in PBS) for 10 min at RT. Antigen retrieval was
then performed by microwave treatment in a citrate buffer for 15 min. Sections were washed in
TBS-T (1X TBS with 0.05%Tween-20) followed by blocking for 30 min at RT in blocking buffer (5%
goat serum, 2.5% BSA in TBS). Slides were then blocked using the Avidin/Biotin Blocking Kit (Vector
Labs). For staining, slides were incubated overnight in a humidified chamber at 4˚C with 1:200 rat
anti-CD45 (Invitrogen clone 30-F11, #14-0451-82) and 1:400 rabbit anti-RFP (Rockland, #600-401379) antibodies diluted in 50% blocking buffer. After primary staining, slides were washed in TBS-T
and then incubated with HRP-conjugated anti-rat IgG secondary (1:500 in 50% blocking buffer) for
30 min at RT. For fluorescent detection of CD45, slides were washed and then incubated in 1:50
FITC Tyramide reagent (PerkinElmer, # NEL701A001KT) for 8 min at RT. For fluorescent detection of
RFP, slides were washed and incubated in AlexaFluor 594-conjugated anti-rabbit IgG secondary
(1:500 in 50% blocking buffer) for 30 min at RT. Stained slides were washed and mounted using ProLong Gold with DAPI (Invitrogen).

Osx staining
HSCs, BMSC or whole bone marrow cells were plated overnight on coverslips coated with FBS for
30 min at RT then cells. Cells were fixed in 4% PFA for 15 min, washed and permeabilized with PBS/
0.3%TritonX-100 for 3 min. Blocking was performed with 5% normal serum in permeabilization buffer
for 1 hr at RT. Anti-Osx antibody (Abcam, #ab227820) was dissolved 1:500 in a buffer containing
PBS/0.3%TritonX-100/1%BSA and incubated ON at 4˚C. For fluorescent detection, coverslips were
washed and incubated in AlexaFluor 488-conjugated anti-rabbit secondary antibody (1:1000) in PBS/

Ricci et al. eLife 2020;9:e54659. DOI: https://doi.org/10.7554/eLife.54659

23 of 29

Research article

Cancer Biology Immunology and Inflammation

0.3%TritonX-100/1%BSA for 1 hr at RT. Stained slides were washed and mounted using VECTASHIELD Mounting Medium containing DAPI (Vector Laboratories, CA USA). Fluorescent signals were
captured by using a Nikon Eclipse 80i microscope and a Nikon DS-Qi1MC camera (Nikon, CO,
USA).

Real Time PCR
Total RNA was extracted with TRIzol (Invitrogen, CA USA) and quantified on a ND-1000 spectrophotometer (NanoDrop Technologies). The cDNA was synthesized with 1 mg RNA using High Capacity
cDNA Reverse Transcription Kit (#4368814, Applied Biosystems, CA USA).
For purified hematopoietic precursors (HSC, MPP, CLP and CMP) total RNA was extracted using
the NucleoSpin RNA XS kit (Macherey-Nagel #740902) and reverse transcribed with the SuperScript
VILO kit (Invitrogen #11754–050).
The amount of each gene was determined using Power SYBR Green mix on 7300 Real-Time PCR
System (Applied Biosystems). Cyclophilin mRNA was used as housekeeping control. Specific primers
for mice were as follows: Cyclophilin, 5’-AGC ATA CAG GTC CTG GCA TC-3’ and 5’-TTC ACC TTC
CCA AAG ACC AC-3’; Osterix, 5’-AAG GGT GGG TAG TCA TTT GCA-3’ and 5’-CCC TTC TCA
AGC ACC AAT GG-3’; S100a4 (Fsp1), 5’-TGA GCA ACT TGG ACA GCA ACA-3’ and 5’-TTC CGG
GGT TCC TTA TCT GGG-3’; Acta2 (a-SMA), 5’-GTC CCA GAC ATC AGG GAG TAA-3’ and 5’-TCG
GAT ACT TCA GCG TCA GGA-3’; Col1a1, 5’-GGC CTT GGA GGA AAC TTT GC-3’ and 5’-GGG
ACC CAT TGG ACC TGA AC-3’; Bglap (Osteocalcin), 5’-GGA CTG AGG CTC TGT GAG GT-3’ and
5’-CAG ACA CCA TGA GGA CCA TC-3’; Runx2, 5’-GTT ATG AAA AAC CAA GTA GCC AGG-3’
and 5’-GTA ATC TGA CTC TGT CCT TGT GGA-3’; Ibsp (Bsp), 5’-AGG ACT AGG GGT CAA ACA C3’ and 5’-AGT AGC GTG GCC GGT ACT TA-3’; Alpl (Tnap), 5’-GGG GAC ATG CAG TAT GAG TT3’ and 5’-GGC CTG GTA GTT GTT GTG AG-3’. The relative quantification in gene expression was
determined using the 2-DDCt method.

RNA sequencing and analysis
Single cell suspensions were prepared from fresh tumor upon sacrifice. Tumors were minced and
digested as described above. Tumor stromal cells were separated from the GFP+ tumor cells and
sorted based on the expression, or lack of thereof, of TdT and CD45 markers.
Library preparation was performed with 10 ng of total RNA and integrity was determined using
an Agilent bioanalyzer. ds-cDNA was prepared using the SMARTer Ultra Low RNA kit for Illumina
Sequencing (Clontech) per manufacturer’s protocol. The cDNA was fragmented using a Covaris
E220 sonicator using peak incident power 18, duty factor 20%, cycles/burst 50, for a 120 s. cDNA
was blunt ended, had an A base added to the 3’ ends, and then had Illumina sequencing adapters
ligated to the ends. Ligated fragments were then amplified for 12 cycles using primers incorporating
unique index tags. Fragments were sequenced on an Illumina HiSeq 3000 using single end reads
extending 50 bases. Basecalls and demultiplexing were performed with Illumina’s bcl2fastq software
and a custom python demultiplexing program with a maximum of one mismatch in the indexing
read. RNA-seq reads were then aligned to the Mus musculus Ensembl release 76 top-level assembly
with STAR version 2.0.4b (Dobin et al., 2013). Gene counts were derived from the number of
uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5 (Liao et al., 2014). Isoform expression of known Ensembl transcripts were estimated with Sailfish version 0.6.13
(Patro et al., 2017). Sequencing performance was assessed with RSeQC version 2.3 (Wang et al.,
2012).
All gene counts were then imported into the R/Bioconductor package EdgeR (Robinson et al.,
2010) and TMM normalization size factors were calculated to adjust for samples for differences in
library size. Ribosomal genes and genes not expressed in at least two samples greater than one
count-per-million were excluded from further analysis. The TMM size factors and the matrix of counts
were then imported into the R/Bioconductor package Limma (Ritchie et al., 2015) and weighted
likelihoods based on the observed mean-variance relationship of every gene and sample were then
calculated with Limma’s voomWithQualityWeights (Liu et al., 2015). The data were then fitted to a
Limma generalized linear model to test for changes in a single cell population relative to the mean
of all other populations to find only genes that were uniquely up-regulated with Benjamini-Hochberg
false-discovery rate adjusted p-values less than or equal to 0.05. For each group of cells, global
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perturbations in known Gene Ontology (GO) terms were then measured using the R/Bioconductor
package GAGE (Luo et al., 2009) to quantify the mean log two fold-changes of ll genes in a given
term versus the background log two fold-changes of all genes found outside the respective term.
Only globally up-regulated GO terms with Benjamini-Hochberg false-discovery rate adjusted p-values less than or equal to 0.05 were considered for comparison across populations.
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